Stefanie Hennig
Stefanie Hennig has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Christine Elizabeth Staatz
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
13 shared publications - Claire Elizabeth Wainwright
Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, South Brisbane, Queensland, Australia
6 shared publications - Andrew C. Hooker
Department of Pharmacy Uppsala University Uppsala Sweden
5 shared publications Bruce G. Charles
School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
5 shared publications- Carolina Consuelo Llanos-Paez
School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
5 shared publications Joakim Nyberg
Uppsala University
5 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 71
Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia
- 17 July 2026
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 71
Open AccessPopulation pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia
- 23 May 2024
- Published by University of Queensland Library
Population pharmacokinetics of itraconazole
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 23 May 2024
- Published by University of Queensland Library
Population pharmacokinetics of itraconazole
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- Open Access
- 17 January 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (4) , 1066-1080
A physiological approach to renal clearance: From premature neonates to adults
Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance.Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed‐effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution.Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non‐GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug‐specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non‐GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50‐5.69) (gentamicin), 7.77 L/h (95% CI 7.26‐8.19) (amikacin) and 4.70 L/h (95% CI 4.61‐4.80) (vancomycin).Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention.
- 17 January 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (4) , 1066-1080
Open AccessA physiological approach to renal clearance: From premature neonates to adults
Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance.Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed‐effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution.Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non‐GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug‐specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non‐GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50‐5.69) (gentamicin), 7.77 L/h (95% CI 7.26‐8.19) (amikacin) and 4.70 L/h (95% CI 4.61‐4.80) (vancomycin).Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention.
- Open Access
- 3 November 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (11) , 1569-1572
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology
- 3 November 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (11) , 1569-1572
Open AccessRole of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology
- Open Access
- 24 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (6) , 743-747
Barriers to global pharmacometrics: educational challenges and opportunities across the globe
- 24 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (6) , 743-747
Open AccessBarriers to global pharmacometrics: educational challenges and opportunities across the globe
- Open Access
- 14 October 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (3) , 1162-1175
Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients
Aim Existing tacrolimus population pharmacokinetic models are unsuitable for guiding tacrolimus dosing in heart transplant recipients. This study aimed to develop and evaluate a population pharmacokinetic model for tacrolimus in heart transplant recipients that considers the tacrolimus-azole antifungal interaction. Methods Data from heart transplant recipients (n = 87) administered the oral immediate-release formulation of tacrolimus (Prograf®) were collected. Routine drug monitoring data, principally trough concentrations, were used for model building (n = 1099). A published tacrolimus model was used to inform the estimation of Ka, V2/F, Q/F and V3/F. The effect of concomitant azole antifungal use on tacrolimus CL/F was quantified. Fat-free mass was implemented as a covariate on CL/F, V2/F, V3/F and Q/F on an allometry scale. Subsequently, stepwise covariate modelling was performed. Significant covariates influencing tacrolimus CL/F were included in the final model. Robustness of the final model was confirmed using prediction-corrected visual predictive check (pcVPC). The final model was externally evaluated for prediction of tacrolimus concentrations of the fourth dosing occasion (n = 87) from one to three prior dosing occasions. Results Concomitant azole antifungal therapy reduced tacrolimus CL/F by 80%. Haematocrit (∆OFV = −44, P < .001) was included in the final model. The pcVPC of the final model displayed good model adequacy. One recent drug concentration is sufficient for the model to guide tacrolimus dosing. Conclusion A population pharmacokinetic model that adequately describes tacrolimus pharmacokinetics in heart transplant recipients, considering the tacrolimus–azole antifungal interaction was developed. Prospective evaluation is required to assess its clinical utility to improve patient outcomes.
- 14 October 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (3) , 1162-1175
Open AccessAdaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients
Aim Existing tacrolimus population pharmacokinetic models are unsuitable for guiding tacrolimus dosing in heart transplant recipients. This study aimed to develop and evaluate a population pharmacokinetic model for tacrolimus in heart transplant recipients that considers the tacrolimus-azole antifungal interaction. Methods Data from heart transplant recipients (n = 87) administered the oral immediate-release formulation of tacrolimus (Prograf®) were collected. Routine drug monitoring data, principally trough concentrations, were used for model building (n = 1099). A published tacrolimus model was used to inform the estimation of Ka, V2/F, Q/F and V3/F. The effect of concomitant azole antifungal use on tacrolimus CL/F was quantified. Fat-free mass was implemented as a covariate on CL/F, V2/F, V3/F and Q/F on an allometry scale. Subsequently, stepwise covariate modelling was performed. Significant covariates influencing tacrolimus CL/F were included in the final model. Robustness of the final model was confirmed using prediction-corrected visual predictive check (pcVPC). The final model was externally evaluated for prediction of tacrolimus concentrations of the fourth dosing occasion (n = 87) from one to three prior dosing occasions. Results Concomitant azole antifungal therapy reduced tacrolimus CL/F by 80%. Haematocrit (∆OFV = −44, P < .001) was included in the final model. The pcVPC of the final model displayed good model adequacy. One recent drug concentration is sufficient for the model to guide tacrolimus dosing. Conclusion A population pharmacokinetic model that adequately describes tacrolimus pharmacokinetics in heart transplant recipients, considering the tacrolimus–azole antifungal interaction was developed. Prospective evaluation is required to assess its clinical utility to improve patient outcomes.
- Open Access
- 16 June 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (8) , 1002-1017
Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance
This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan exposure and the ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric stem cell transplantation recipients. Daily serial blood sampling was performed and concentration-time data were analyzed using a nonlinear mixed-effects approach. The developed PK model was used to assess achievement of target exposure under six dose-adjustment scenarios based on simulations performed in RStudio (RxODE package)(R). A total of 2491 busulfan plasma concentration-time measurements were collected from 95 patients characterizing 379 dosing days. A two-compartment model with time-associated CL best described the data with a typical CL of 14.5 L/h for an adult male with 62 kg normal fat mass (NFM; equivalent to 70 kg total body weight), typical volume of distribution central compartment (V1) of 40.6 L/59 kg NFM (equivalent to 70 kg total body weight), and typical volume of distribution peripheral compartment of 3.57 L/62 kg NFM. Model interindividual variability in CL and V1 was 14.7% and 34.9%, respectively, and interoccasional variability in CL was 6.6%. Patient size described by NFM, a maturation component, and time since start of treatment significantly influenced CL. Simulations demonstrated that using model-based exposure estimates with each dose, and either a proportional dose-adjustment calculation or model-based calculated individual CL estimates to support dose adjustments, increased proportion of subjects attaining cumulative exposure within 5% of target compared with using noncompartmental analysis (100% vs. 0%). A time-associated reduction in CL during once-daily busulfan treatment was described.
- 16 June 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (8) , 1002-1017
Open AccessPopulation pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance
This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan exposure and the ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric stem cell transplantation recipients. Daily serial blood sampling was performed and concentration-time data were analyzed using a nonlinear mixed-effects approach. The developed PK model was used to assess achievement of target exposure under six dose-adjustment scenarios based on simulations performed in RStudio (RxODE package)(R). A total of 2491 busulfan plasma concentration-time measurements were collected from 95 patients characterizing 379 dosing days. A two-compartment model with time-associated CL best described the data with a typical CL of 14.5 L/h for an adult male with 62 kg normal fat mass (NFM; equivalent to 70 kg total body weight), typical volume of distribution central compartment (V1) of 40.6 L/59 kg NFM (equivalent to 70 kg total body weight), and typical volume of distribution peripheral compartment of 3.57 L/62 kg NFM. Model interindividual variability in CL and V1 was 14.7% and 34.9%, respectively, and interoccasional variability in CL was 6.6%. Patient size described by NFM, a maturation component, and time since start of treatment significantly influenced CL. Simulations demonstrated that using model-based exposure estimates with each dose, and either a proportional dose-adjustment calculation or model-based calculated individual CL estimates to support dose adjustments, increased proportion of subjects attaining cumulative exposure within 5% of target compared with using noncompartmental analysis (100% vs. 0%). A time-associated reduction in CL during once-daily busulfan treatment was described.
- 24 September 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 89 (4) , 571-572
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
- 24 September 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 89 (4) , 571-572
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
- 23 September 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (4) , 1751-1772
Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients
Background and Aim: Identification of the most appropriate population pharmacokinetic model‐based Bayesian estimation is required prior to its implementation in routine clinical practice to inform tacrolimus dosing decisions. This study aimed to determine the predictive performances of relevant population pharmacokinetic models of tacrolimus developed from various solid organ transplant recipient populations in adult heart transplant recipients, stratified based on concomitant azole antifungal use. Concomitant azole antifungal therapy alters tacrolimus pharmacokinetics substantially, necessitating dose adjustments.Methods: Population pharmacokinetic models of tacrolimus were selected (n = 17) for evaluation from a recent systematic review. The models were transcribed and implemented in NONMEM version 7.4.3. Data from 85 heart transplant recipients (2387 tacrolimus concentrations) administered the oral immediate‐release formulation of tacrolimus (Prograf) were obtained up to 391 days post‐transplant. The performance of each model was evaluated using: (i) prediction‐based assessment (bias and imprecision) of the individual predicted tacrolimus concentration of the fourth dosing occasion (MAXEVAL = 0, FOCE‐I) from 1–3 prior dosing occasions; and (ii) simulation‐based assessment (prediction‐corrected visual predictive check). Both assessments were stratified based on concomitant azole antifungal use.Results: Regardless of the number of prior dosing occasions (1–3) and concomitant azole antifungal use, all models demonstrated unacceptable individual predicted tacrolimus concentration of the fourth dosing occasion (n = 152). The prediction‐corrected visual predictive check graphics indicated that these models inadequately predicted observed tacrolimus concentrations.Conclusion: All models evaluated were unable to adequately describe tacrolimus pharmacokinetics in adult heart transplant recipients included in this study. Further work is required to describe tacrolimus pharmacokinetics for our heart transplant recipient cohort.
- 23 September 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (4) , 1751-1772
Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients
Background and Aim: Identification of the most appropriate population pharmacokinetic model‐based Bayesian estimation is required prior to its implementation in routine clinical practice to inform tacrolimus dosing decisions. This study aimed to determine the predictive performances of relevant population pharmacokinetic models of tacrolimus developed from various solid organ transplant recipient populations in adult heart transplant recipients, stratified based on concomitant azole antifungal use. Concomitant azole antifungal therapy alters tacrolimus pharmacokinetics substantially, necessitating dose adjustments.Methods: Population pharmacokinetic models of tacrolimus were selected (n = 17) for evaluation from a recent systematic review. The models were transcribed and implemented in NONMEM version 7.4.3. Data from 85 heart transplant recipients (2387 tacrolimus concentrations) administered the oral immediate‐release formulation of tacrolimus (Prograf) were obtained up to 391 days post‐transplant. The performance of each model was evaluated using: (i) prediction‐based assessment (bias and imprecision) of the individual predicted tacrolimus concentration of the fourth dosing occasion (MAXEVAL = 0, FOCE‐I) from 1–3 prior dosing occasions; and (ii) simulation‐based assessment (prediction‐corrected visual predictive check). Both assessments were stratified based on concomitant azole antifungal use.Results: Regardless of the number of prior dosing occasions (1–3) and concomitant azole antifungal use, all models demonstrated unacceptable individual predicted tacrolimus concentration of the fourth dosing occasion (n = 152). The prediction‐corrected visual predictive check graphics indicated that these models inadequately predicted observed tacrolimus concentrations.Conclusion: All models evaluated were unable to adequately describe tacrolimus pharmacokinetics in adult heart transplant recipients included in this study. Further work is required to describe tacrolimus pharmacokinetics for our heart transplant recipient cohort.
- Open Access
- 12 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (2) , 403-415
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
Aims: Abacavir is part of WHO‐recommended regimens to treat HIV in children under 15 years of age. In a pooled analysis across four studies, we describe abacavir population pharmacokinetics to investigate the influence of age, concomitant medications, malnutrition and formulation.Methods: A total of 230 HIV‐infected African children were included, with median (range) age of 2.1 (0.1–12.8) years and weight of 9.8 (2.5–30.0) kg. The population pharmacokinetics of abacavir was described using nonlinear mixed‐effects modelling.Results: Abacavir pharmacokinetics was best described by a two‐compartment model with first‐order elimination, and absorption described by transit compartments. Clearance was predicted around 54% of its mature value at birth and 90% at 10 months. The estimated typical clearance at steady state was 10.7 L/h in a child weighing 9.8 kg co‐treated with lopinavir/ritonavir, and was 12% higher in children receiving efavirenz. During coadministration of rifampicin‐based antituberculosis treatment and super‐boosted lopinavir in a 1:1 ratio with ritonavir, abacavir exposure decreased by 29.4%. Malnourished children living with HIV had higher abacavir exposure initially, but this effect waned with nutritional rehabilitation. An additional 18.4% reduction in clearance after the first abacavir dose was described, suggesting induction of clearance with time on lopinavir/ritonavir‐based therapy. Finally, absorption of the fixed dose combination tablet was 24% slower than the abacavir liquid formulation.Conclusion: In this pooled analysis we found that children on lopinavir/ritonavir or efavirenz had similar abacavir exposures, while concomitant TB treatment and super‐boosted lopinavir gave significantly reduced abacavir concentrations.
- 12 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (2) , 403-415
Open AccessAbacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
Aims: Abacavir is part of WHO‐recommended regimens to treat HIV in children under 15 years of age. In a pooled analysis across four studies, we describe abacavir population pharmacokinetics to investigate the influence of age, concomitant medications, malnutrition and formulation.Methods: A total of 230 HIV‐infected African children were included, with median (range) age of 2.1 (0.1–12.8) years and weight of 9.8 (2.5–30.0) kg. The population pharmacokinetics of abacavir was described using nonlinear mixed‐effects modelling.Results: Abacavir pharmacokinetics was best described by a two‐compartment model with first‐order elimination, and absorption described by transit compartments. Clearance was predicted around 54% of its mature value at birth and 90% at 10 months. The estimated typical clearance at steady state was 10.7 L/h in a child weighing 9.8 kg co‐treated with lopinavir/ritonavir, and was 12% higher in children receiving efavirenz. During coadministration of rifampicin‐based antituberculosis treatment and super‐boosted lopinavir in a 1:1 ratio with ritonavir, abacavir exposure decreased by 29.4%. Malnourished children living with HIV had higher abacavir exposure initially, but this effect waned with nutritional rehabilitation. An additional 18.4% reduction in clearance after the first abacavir dose was described, suggesting induction of clearance with time on lopinavir/ritonavir‐based therapy. Finally, absorption of the fixed dose combination tablet was 24% slower than the abacavir liquid formulation.Conclusion: In this pooled analysis we found that children on lopinavir/ritonavir or efavirenz had similar abacavir exposures, while concomitant TB treatment and super‐boosted lopinavir gave significantly reduced abacavir concentrations.